These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27890815)

  • 21. Permeation characteristics of a hydrophilic basic compound across a bio-mimetic artificial membrane.
    Sugano K; Nabuchi Y; Machida M; Asoh Y
    Int J Pharm; 2004 May; 275(1-2):271-8. PubMed ID: 15081157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug permeation through synthetic lipid membranes. Part 10: The effects of diffusion layers on the permeation process (author's transl)].
    Fürst W; Neubert R; Reppel L
    Pharmazie; 1980 Feb; 35(2):106-9. PubMed ID: 7384178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drug permeation through synthetic lipid membranes. Part 13: The effects of tensides on the permeation of ionized drugs (author's transl)].
    Fürst W; Neubert R; Förster B; Reppel L
    Pharmazie; 1980; 34(5-6):315-6. PubMed ID: 7413708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesterol's decoupling effect on membrane partitioning and permeability revisited: is there anything beyond Fick's law of diffusion?
    Missner A; Horner A; Pohl P
    Biochim Biophys Acta; 2008 Oct; 1778(10):2154-6. PubMed ID: 18510944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
    Tam KY; Avdeef A; Tsinman O; Sun N
    J Med Chem; 2010 Jan; 53(1):392-401. PubMed ID: 19947605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the distribution of drugs in saliva and blood plasma.
    Feller K; le Petit G
    Int J Clin Pharmacol Biopharm; 1977 Oct; 15(10):468-9. PubMed ID: 21854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Faster determination of membrane permeabilities without using the lag time method.
    Bellantone RA; Nicolettos N; Plakogiannis FM
    Int J Pharm; 2002 Nov; 248(1-2):81-92. PubMed ID: 12429462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs.
    Miller JM; Dahan A; Gupta D; Varghese S; Amidon GL
    J Control Release; 2009 Jul; 137(1):31-7. PubMed ID: 19264104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Permeability through DOPC/dodecane membranes: measurement and LFER modelling.
    Huque FT; Box K; Platts JA; Comer J
    Eur J Pharm Sci; 2004 Nov; 23(3):223-32. PubMed ID: 15489123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transport mechanisms of flavanone aglycones across Caco-2 cell monolayers and artificial PAMPA membranes.
    Kobayashi S; Nagai T; Konishi Y; Tanabe S; Morimoto K; Ogihara T
    J Pharm Pharmacol; 2012 Jan; 64(1):52-60. PubMed ID: 22150672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Extracellular Binding Proteins in the Cellular Uptake of Drugs: Impact on Quantitative In Vitro-to-In Vivo Extrapolations of Toxicity and Efficacy in Physiologically Based Pharmacokinetic-Pharmacodynamic Research.
    Poulin P; Burczynski FJ; Haddad S
    J Pharm Sci; 2016 Feb; 105(2):497-508. PubMed ID: 26173749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New biomimetic barrier Permeapad™ for efficient investigation of passive permeability of drugs.
    di Cagno M; Bibi HA; Bauer-Brandl A
    Eur J Pharm Sci; 2015 Jun; 73():29-34. PubMed ID: 25840123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative aspects of drug permeation across in vitro and in vivo barriers.
    Krämer SD
    Eur J Pharm Sci; 2016 May; 87():30-46. PubMed ID: 26493585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An extended model based on the modified Nernst-Planck equation for describing transdermal iontophoresis of weak electrolytes.
    Imanidis G; Luetolf P
    J Pharm Sci; 2006 Jul; 95(7):1434-47. PubMed ID: 16724334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SC lipid model membranes designed for studying impact of ceramide species on drug diffusion and permeation--part II: diffusion and permeation of model drugs.
    Ochalek M; Podhaisky H; Ruettinger HH; Wohlrab J; Neubert RH
    Eur J Pharm Biopharm; 2012 Oct; 82(2):360-6. PubMed ID: 22750439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new in vitro system for evaluation of passive intestinal drug absorption: establishment of a double artificial membrane permeation assay.
    Kataoka M; Tsuneishi S; Maeda Y; Masaoka Y; Sakuma S; Yamashita S
    Eur J Pharm Biopharm; 2014 Nov; 88(3):840-6. PubMed ID: 25304077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Permeation prediction of M100240 using the parallel artificial membrane permeability assay.
    Hwang KK; Martin NE; Jiang L; Zhu C
    J Pharm Pharm Sci; 2003; 6(3):315-20. PubMed ID: 14738711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partitioning phenomena in dosage form and biopharmaceutical design. 3. Some partitioning considerations in drug absorption, distribution, response and elimination.
    Schumacher GE
    Am J Hosp Pharm; 1972 Apr; 29(4):339-43. PubMed ID: 5025265
    [No Abstract]   [Full Text] [Related]  

  • 40. Application of numerical methods for diffusion-based modeling of skin permeation.
    Frasch HF; Barbero AM
    Adv Drug Deliv Rev; 2013 Feb; 65(2):208-20. PubMed ID: 22261307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.